Quick Take: The funding comes from a number of angel investors with experience in the industry. Funding will support expansion of Osmind’s neuropsychiatry software platform and team growth Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and expand its electronic health…

With the breakthrough of psychedelic medicine just on the horizon, right now is a very exciting time to be an investor. But what is pushing the psychedelic revolution even further is the global pandemic. The isolation of lockdown has had a significant impact on the mental well-being of many people.

Osmind is adding Dr. Robin Carhart-Harris as a Scientific Advisor.

There’s a significant challenge that many therapists and patients face when going through psychedelic therapy: time. The process simply requires a lot of time in the clinic and under the therapist’s care to deliver the best results. But what happens when the patient goes home? How does their mood shift in the days, weeks, and…